Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of empagliflozin on HbA1c in patients with type 2 diabetes
IRCT20190618043934N30Phase 3Completed
- Sponsor
- Vice Chancellor for Research, Birjand University of Medical Sciences
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Vice Chancellor for Research, Birjand University of Medical Sciences. Primary endpoint: Change in serum glycosylated hemoglobin (HbA1c). Started Nov 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20190618043934N30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190618043934N30.